BPC-157 dosing: what the studies used

If you search for "BPC-157 dose" you will find numbers repeated with confidence across forums, vendor pages and clinic brochures. Most of them trace back to the same place: rodent studies that were never designed to produce a human dosing protocol. This article walks through what those studies actually administered, how the numbers got from rats to Reddit, and why no defensible human dose exists today. For the full compound profile, see the BPC-157 peptide page.

What the animal studies used

The majority of published BPC-157 work comes from the University of Zagreb group led by Predrag Sikiric. Their standard design uses intraperitoneal injection in Wistar rats at three dose levels: 10 mcg/kg, 10 ng/kg and 10 pg/kg body weight, administered once daily starting within 30 minutes of injury^[1]. That three-tier protocol appears in the Achilles tendon detachment model (Krivic et al., 2006), the ileoileal anastomosis model (Vuksic et al., 2007) and the medial-collateral-ligament transection model (Cerovecki et al., 2010).

Cerovecki et al. also tested two additional routes: topical application at 1.0 mcg per gram of neutral cream, and oral delivery at 0.16 mcg/ml in drinking water (roughly 12 ml per day per rat)^[2]. Both routes showed healing improvements at 90 days after MCL transection, though the oral data is thinner than the injection data across the broader literature.

A separate Chinese research group (Xu et al., 2020) ran preclinical safety and pharmacokinetic work in rats and dogs, testing intramuscular doses of 20, 100 and 500 mcg/kg and intravenous doses of 20 mcg/kg^[3]. The elimination half-life was less than 30 minutes across species. That study proposed a clinical starting dose of 200 mcg per person per day (about 3 mcg/kg for a 70 kg adult), but this number has not been validated in a controlled human trial.

How the 200 to 500 mcg range reached the internet

The figures most often quoted online (200 mcg to 500 mcg, once or twice daily, subcutaneously) are allometric extrapolations. The method takes a rodent dose in mcg/kg, applies a body-surface-area conversion factor (typically 6.2 for rat-to-human), and produces a human-equivalent dose. The conversion is standard pharmacology for first-in-human dose estimation. It is not a validated therapeutic dose. The number tells you roughly where a phase-1 trial might start; it does not tell you what works, what is safe at repeated exposure, or what the dose-response curve looks like in people.

No published phase-2 or phase-3 randomised controlled trial of BPC-157 exists for any indication. The 200 to 500 mcg range has been repeated so many times across forums, vendor FAQ pages and clinic intake forms that it reads like settled science, but it is an estimate layered on animal data, not a clinical finding. The Xu et al. safety study proposed 200 mcg per person per day as a candidate clinical dose; that figure has not been tested against a placebo in a human population.

Routes of administration in the literature

The Zagreb group has tested intraperitoneal, intragastric (oral), topical (cream) and direct local application. The Chinese pharmacokinetic group tested intramuscular and intravenous routes^[3]. Subcutaneous injection, the route most commonly discussed online, appears less frequently in the formal literature than intraperitoneal. That matters because bioavailability differs by route: intramuscular bioavailability was approximately 14 to 19% in rats and 45 to 51% in dogs. The subcutaneous figure is not well characterised in published work.

The oral route is worth noting separately. The Zagreb group's ligament study delivered BPC-157 in drinking water at very low concentrations and still reported healing effects at 90 days. If that finding replicates, it would be significant for any future clinical programme because oral delivery avoids the injection-site and sterility concerns that complicate grey-market peptide use. But the oral data set is small and has not been independently reproduced.

What we still do not know

The list is long. There is no published human dose-response study. There is no characterised human safety profile from a controlled trial. There is no data on drug interactions, chronic-use effects, or outcomes in pregnancy, paediatric or geriatric populations. There is no independent replication of the Zagreb group's tendon and gut findings by a lab without co-author overlap. The compound is not approved by the FDA, the EMA, the MHRA or any national medicines agency we track. WADA lists it under S0 (non-approved substances), and the US Department of Defense's Operation Supplement Safety classifies it as a prohibited peptide and an unapproved drug.

^[4] The FDA's Pharmacy Compounding Advisory Committee is scheduled to meet on 23 to 24 July 2026 to discuss BPC-157's eligibility as a bulk drug substance for compounding under section 503A. That meeting will shape the US compounding landscape but will not, by itself, generate the missing efficacy and safety data. For per-country regulatory status, see the BPC-157 regulation section.

The bottom line for readers

Every dose number you see for BPC-157 comes from animal work or from allometric maths applied to animal work. The compound has genuine preclinical interest, particularly in tendon and gut injury models, but the jump from "10 mcg/kg IP in a rat" to "250 mcg SC twice a day in a human" is an extrapolation, not evidence. If you are considering BPC-157, that conversation belongs with a clinician who knows your medical history, not with a vendor's dosing chart.